Cardiol Therapeutics (TSE:CRDL) Releases Earnings Results

Cardiol Therapeutics (TSE:CRDL) released its quarterly earnings data on Monday. The company reported C($0.10) earnings per share for the quarter, FiscalAI reports.

Cardiol Therapeutics Trading Up 1.7%

TSE:CRDL opened at C$1.83 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 4.16 and a quick ratio of 6.84. The business’s 50-day simple moving average is C$1.70 and its 200-day simple moving average is C$1.52. Cardiol Therapeutics has a fifty-two week low of C$1.23 and a fifty-two week high of C$2.33. The stock has a market capitalization of C$204.37 million, a PE ratio of -4.69 and a beta of 0.24.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.